FOUNDATIONONE®CDx

PATIENT

TUMOR TYPE
Lung non-small cell lung carcinoma (NOS)

REPORT DATE

COUNTRY CODE
EC

ORDERED TEST #

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Lung non-small cell lung carcinoma (NOS)
NAME
DATE OF BIRTH
SEX
MEDICAL RECORD #

PHYSICIAN
ORDERING PHYSICIAN
MEDICAL FACILITY
ADDITIONAL RECIPIENT
MEDICAL FACILITY ID
PATHOLOGIST

SPECIMEN
SPECIMEN SITE
SPECIMEN ID
SPECIMEN TYPE
DATE OF COLLECTION
SPECIMEN RECEIVED

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 5 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

EGFR exon 19 deletion (E746_A750del)
APC Y158fs*12
FANCL R68*
TSC1 G464fs*68
ASXL1 G967del

7 Disease relevant genes with no reportable alterations: ***ALK, BRAF, ERBB2, KRAS, MET, RET, ROS1***

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Afatinib** (p. 7), **Dacomitinib** (p. 8), **Erlotinib** (p. 8), **Gefitinib** (p. 9), **Osimertinib** (p. 9)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: ***ASXL1* G967del** (p. 6)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 5 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***EGFR* -** exon 19 deletion (E746_A750del)	Afatinib [1]	none
	Dacomitinib [1]	
	Erlotinib [1]	
	Gefitinib [1]	
10 Trials *see p. 12*	Osimertinib [1]	
***APC* -** Y158fs*12	none	none
3 Trials *see p. 11*		
***FANCL* -** R68*	none	none
10 Trials *see p. 14*		
***TSC1* -** G464fs*68	none	none
10 Trials *see p. 16*		

[ ] *NCCN category*

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

ASXL1 - G967del ..... p. 6

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

ASXL1 - G967del ..... p. 6

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-H is generally infrequent in NSCLC, reported in fewer than 1% of samples across several large studies[6-11], whereas data on the reported incidence of MSI-H in SCLC has been limited and conflicting[12-15]. One study reported MSI-H in lung adenocarcinoma patients with smoking history, and 3 of 4 MSI-H patients examined also had metachronous carcinomas in other organs, although this has not been investigated in large scale studies[6]. Published data investigating the prognostic implications of MSI in NSCLC are limited (PubMed, Oct 2021).

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[16]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[16-18]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[19-21]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[16,18,20-21].

BIOMARKER

Tumor Mutational Burden

RESULT
5 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[22-24], anti-PD-1 therapies[22-25], and combination nivolumab and ipilimumab[26-31]. Multiple clinical trials of PD-1- or PD-L1-targeting immune checkpoint inhibitors or combination of PD-1 and CTLA-4 inhibitors in NSCLC have reported that patients with tumors harboring TMB ≥10 Muts/Mb derive greater clinical benefit from these therapies than those with TMB <10 Muts/Mb (based on this assay or others); similarly, higher efficacy of anti-PD-1 or anti-PD-L1 immunotherapy for treatment of patients with NSCLC, compared with the use of chemotherapy, has been observed more significantly in cases of TMB ≥10 Muts/Mb (based on this assay or others);[22-23,26-28,32-39]. Improved OS of patients with NSCLC treated with pembrolizumab plus chemotherapy relative to chemotherapy only[40], or those treated with nivolumab plus ipilimumab also relative to chemotherapy[41], has been observed across all TMB levels.

FREQUENCY & PROGNOSIS

A large-scale genomic analysis found that unspecified lung non-small cell lung carcinoma (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma (SCC) samples harbored median TMBs between 6.3 and 9 Muts/Mb, and 12% to 17% of cases had an elevated TMB of greater than 20 Muts/Mb[42]. Lower TMB is observed more commonly in NSCLCs harboring known driver mutations (EGFR, ALK, ROS1, or MET) with the exception of BRAF or KRAS mutations, which are commonly observed in elevated TMB cases[43]. Although some studies have reported a lack of association between smoking and mutational burden in NSCLC[44-45], several other large studies did find a strong association with increased TMB[46-49]. TMB >10 muts/Mb was found to be more frequent in NSCLC metastases compared with primary tumors for both adenocarcinoma (38% vs. 25%) and SCC (41% vs. 35%) subtypes[50]. A meta-analysis of 19 studies of immune checkpoint inhibitor-treated NSCLC (n = 2,315 patients) demonstrated that high TMB predicted a significantly longer OS than low TMB (HR = 0.70), and within the high TMB group, immunotherapy was associated with an improved PFS (HR = 0.62, P<0.001), OS (HR = 0.67, P<0.001) and a higher response rate (OR = 2.35, P<0.001) compared to chemotherapy[51]. In contrast, a large study of Chinese patients with untreated lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)[44]. Another study of patients with NSCLC treated with EGFR inhibitors or platinum doublet chemotherapy found elevated TMB to be correlated with poorer prognosis, as well as finding lower TMB in combination with PD-L1 negative status to be significantly associated with longer median survival in patients with lung adenocarcinoma[52]. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC[52-53].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[54-55] and cigarette smoke in lung cancer[32,56], treatment with temozolomide-based chemotherapy in glioma[57-58], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[59-63], and microsatellite instability (MSI)[59,62-63]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[22-23,26-28,32-39,64].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
EGFR

ALTERATION
exon 19 deletion (E746_A750del)

TRANSCRIPT ID
NM_005228

CODING SEQUENCE EFFECT
2236_2250delGAATTAAGAGAAGCA

VARIANT ALLELE FREQUENCY (% VAF)
18.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

For patients with non-small cell lung cancer, EGFR activating mutations may predict sensitivity to EGFR TKIs, including erlotinib[65], gefitinib[66], afatinib[67], dacomitinib[68], and osimertinib[69]; however, the data for patients with other tumor types are limited[70-75]. The Phase 1 CHRYSALIS study of amivantamab monotherapy or in combination with lazertinib for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) has produced encouraging preliminary results for treatment-naive patients and patients who relapsed after treatment with osimertinib with and without chemotherapy, including osimertinib-relapsed patients with biomarkers indicating EGFR/MET-based osimertinib resistance[76-79] . In a Phase 1 trial, the HER3-targeted antibody patritumab deruxtecan elicited an ORR of 39% (22/57, 1 CR) and a median PFS of 8.2 months for patients with non-small cell lung cancer previously treated with an EGFR TKI, many of whom displayed TKI resistance alterations[80]. A Phase 1 trial evaluating the EGFR inhibitor AZD3759 reported a reduction in the volume of brain metastases in 40% (8/20) of patients with previously treated non-small cell lung cancer (NSCLC) harboring either the EGFR L858R alteration or EGFR exon 19 deletion, including 3 confirmed PRs and 3 unconfirmed PRs[81-82]. In a Phase 1/2 trial for advanced NSCLC, the brain-penetrant third-generation EGFR TKI lazertinib enabled ORRs of 54% (69/127) for all evaluable patients and 44% (8/18, intracranial) for patients with brain metastases[83]. A Phase 1 trial evaluating the irreversible pan-HER inhibitor FCN-411 for NSCLC patients who had EGFR mutations and experienced disease progression on standard treatments reported an ORR of 15% with 10/67 patients achieving PR, and a DCR of 73% with 39 additional patients achieving SD[84]. OR was observed in a numerically higher proportion of patients with the EGFR T790M mutation than those without this mutation[84].

— Nontargeted Approaches —

Patients with EGFR-mutated non-squamous metastatic non-small cell lung cancer previously treated with EGFR TKI have benefited from immune checkpoint inhibitors combined with anti-angiogenic and chemotherapy, particularly atezolizumab plus bevacizumab plus carboplatin and paclitaxel (OS HR 0.61 compared with bevacizumab/chemotherapy)[85-87] or sintilimab plus bevacizumab biosimilar plus cisplatin and pemetrexed (PFS HR 0.46 compared with chemotherapy alone)[88].

FREQUENCY & PROGNOSIS

EGFR mutation has been reported in 12-36% of lung adenocarcinomas[48,89-90] and in 4% of lung squamous cell carcinomas[91]. EGFR protein expression/overexpression has been reported in up to 70% of NSCLC cases[92-97]. In addition, expression of EGFR protein has been shown to be higher in lung squamous cell carcinoma samples as compared to lung adenocarcinoma[98-99]. In patients with lung adenocarcinoma, EGFR mutation was a predictor of poor overall survival[100-101]. However, EGFR mutations have been reported to predict improved survival in patients with resected Stage 1-3 lung adenocarcinoma[102] or resected Stage 1 NSCLC[103].

FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide[104]. EGFR exon 19 deletion mutations, such as seen here, have been shown to activate the tyrosine kinase activity of EGFR and to confer sensitivity to EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib[105-107], afatinib[108], osimertinib[109], and dacomitinib[68,110], although limited preclinical data suggest reduced sensitivity to lapatinib[111-112].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
APC

ALTERATION
Y158fs*12

TRANSCRIPT ID
NM_000038

CODING SEQUENCE EFFECT
473delA

VARIANT ALLELE FREQUENCY (% VAF)
46.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved drugs targeting APC inactivation in cancer. Loss of APC function leads to accumulation of beta-catenin and upregulation of WNT pathway transcription programs[113], and potential therapeutic approaches to target this pathway include CBP/beta-catenin antagonists, which interfere with the ability of beta-catenin to interact with transcriptional co-activator CBP[114-115]. In a Phase 1 trial of the CBP/beta-catenin antagonist E7386, 1 patient with APC-mutated small bowel adenocarcinoma achieved a PR with tumor shrinkage of -69% and response duration of 165 days[116]; preclinical data support sensitivity of APC-deficient gastric or colorectal cancer models to E7386[117-118].

FREQUENCY & PROGNOSIS

In the TCGA datasets, APC mutations have been reported in 3.9% of lung adenocarcinomas[90] and 4.5% of lung squamous cell carcinoma samples analyzed[91]. Studies of APC in lung cancer have reported mutations in 5-7% of non-small cell lung cancer (NSCLC) tumors examined[47,119]. In contrast, loss of heterozygosity at the APC/MCC locus has been reported in up to 68% (17/25) of NSCLC, with a higher incidence in squamous cell carcinomas compared to adenocarcinomas[120-121]. Hypermethylation of APC in NSCLC tumors has been reported in a number of studies[122-125]; hypermethylation and lower APC mRNA expression have been associated with poorer survival in patients with NSCLC[121,126]. Solid tumors with WNT/beta-catenin pathway alterations, as seen here, were observed to have significantly less T-cell inflammation in one study[127].

FINDING SUMMARY

APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta-catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation[128]. Alterations such as seen here may disrupt APC function or expression[129-133].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP)[134-136]. The prevalence for FAP in the general population is estimated to be 1:8,300 from birth[137], and in the appropriate clinical context germline testing of APC is recommended.

GENE
FANCL

ALTERATION
R68*

TRANSCRIPT ID
NM_018062

CODING SEQUENCE EFFECT
202C>T

VARIANT ALLELE FREQUENCY (% VAF)
50.1%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies that directly address genomic alterations in FANCL. Clinical evidence in ovarian cancer indicates that FANCL inactivation may confer sensitivity to PARP inhibitors[138-139] .

FREQUENCY & PROGNOSIS

FANCL mutations are most frequently observed in tumors of the prostate (5.3%) and liver (4.0%), and are seen at lower frequency in other tumor types (COSMIC, May 2022)[140]. Published data investigating the prognostic implications of FANCL alterations in solid tumors and hematologic malignancies are limited (PubMed, May 2022). In a prospective study of 255 patients with follicular lymphoma, 2p gain, which includes VRK2, FANCL, and LINC01122, was associated with worse PFS and OS in multivariate analysis[141].

FINDING SUMMARY

FANCL encodes a member of the Fanconi anemia nuclear complex, a multiprotein structure also including the products of FANCA, FANCC, FANCF and FANCG. The activity of this complex is essential to prevention of chromosome breakage caused by DNA damage[142]. Germline mutations in FANCL cause Fanconi anemia, a clinically heterogeneous disorder involving various developmental abnormalities as well as predisposition to cancer; underlying these phenotypes are defects in DNA repair[143]. Alterations such as seen here may disrupt FANCL function or expression[144-151]. Germline mutations in FANCL, such as T367fs*13, have been associated with Fanconi anemia, breast cancer, and ovarian cancer and with an increased risk of esophageal cancer and prostate cancer[152-156].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TSC1

ALTERATION
G464fs*68

TRANSCRIPT ID
NM_000368

CODING SEQUENCE EFFECT
1391delG

VARIANT ALLELE FREQUENCY (% VAF)
38.7%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Loss or inactivation of TSC1 can activate mTOR signaling[157-158]; however, response rates for patients with TSC1-mutated solid tumors treated with MTOR inhibitors such as everolimus and temsirolimus have been low[159-161]. In the prospective NCI-MATCH study, the ORR for patients with various TSC1-mutated solid tumors treated with everolimus was 7.7% (1/13); the single response was reported for a patient with urothelial cancer[159]. In TSC1-mutated renal cell carcinoma (RCC), although responses to MTOR inhibitors have been described in multiple case series and reports[162-166], retrospective analysis of a broader cohort showed no responses in TSC1-mutated RCC (0/7)[160]. Retrospective analyses of the RECORD-3, GRANITE-1, and EVOLVE-1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS[161]. PRs have been reported for patients with TSC1-altered perivascular epithelioid cell tumors[167-168] and epithelial ovarian carcinoma[169] treated with nab-sirolimus.

FREQUENCY & PROGNOSIS

In the TCGA datasets, TSC1 mutations have been reported in ~2% of lung adenocarcinoma cases[90] and 2.2% of lung squamous cell carcinoma cases[91]. One study reported loss of heterozygosity of TSC1 in 19% (16/86) of non-small cell lung cancer tissue samples[170]. Strong cytoplasmic expression of Hamartin was reported in 40.2% of lung adenocarcinomas and in 29% of lung SCCs, with moderate expression in 18.5% of lung adenocarcinomas and 28.5% of lung SCCs in 1 study; in SCLC samples, only 14% expressed strong expression of Hamartin, and 4.7% had moderate expression[171]. Published data investigating the prognostic implications of TSC1 alterations in lung cancers are limited (PubMed, Aug 2021).

FINDING SUMMARY

TSC1 encodes the protein Hamartin, which interacts with Tuberin, the gene product of TSC2, to inhibit and regulate mTOR activity[157,172]. Alterations such as seen here may disrupt TSC1 function or expression[173-175].

POTENTIAL GERMLINE IMPLICATIONS

Inactivating germline mutations in TSC1 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma[176-177]. TSC1 mutations account for approximately 10 to 30% of reported sporadic cases[178]. Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age[179]. In the appropriate clinical context, germline testing of TSC1 is recommended.

GENE
ASXL1

ALTERATION
G967del

TRANSCRIPT ID
NM_015338

CODING SEQUENCE EFFECT
2898_2900delAGG

VARIANT ALLELE FREQUENCY (% VAF)
72.2%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in ASXL1.

FREQUENCY & PROGNOSIS

ASXL1 alterations occur infrequently across various solid tumor types[180] and are not known to act as drivers in any specific solid cancer type[181]. Published data investigating the prognostic implications of ASXL1 alterations in solid tumors are limited (PubMed, May 2022). In the context of clonal hematopoiesis, ASXL1 mutations are significantly enriched in current or former smokers[182].

FINDING SUMMARY

ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors[183-185]. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[186-191]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[186-187]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[192]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[190,193-194]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Afatinib

Assay findings association

EGFR
exon 19 deletion (E746_A750del)

AREAS OF THERAPEUTIC USE

Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) and nonresistant EGFR mutations and for the treatment of patients with metastatic, squamous NSCLC after progression on platinum-based chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[67-68,195-196] , whereas data for patients with other tumor types are limited[70-75,197] .

SUPPORTING DATA

Afatinib has shown significant clinical activity for patients with NSCLC and the EGFR common sensitizing mutations L858R or exon 19 deletions, based on extensive clinical evidence[67,195,198-201] . Two randomized Phase 3 trials reported significantly improved median PFS from afatinib compared with chemotherapy for patients with EGFR common sensitizing mutations (LUX-Lung 3, 13.6 vs. 6.9 months, HR 0.47, p<0.001; LUX-Lung 6, 11.0 vs. 5.6 months, HR 0.28, p<0.0001)[67,195] . However, while afatinib significantly increased OS relative to chemotherapy for patients with EGFR exon 19 alterations in these two trials (LUX-Lung 3, 33.3 vs. 21.1 months, HR=0.54; LUX-Lung 6, 31.4 vs. 18.4 months, HR=0.64), no significant OS differences were observed in treatment for patients with L858R mutation[108]. A similar alteration-specific difference was observed for EGFR-mutated treatment-naive NSCLC in a retrospective analysis, which reported numerically longer median OS from second- versus first-generation EGFR TKIs (48.8 vs. 26.4 months, HR=0.59) for patients with exon 19 deletions, but no substantial difference for patients with L858R (25.4 vs. 20.6 months, HR=0.90)[198]. A Phase 2b study of first-line afatinib compared with gefitinib, also for NSCLC with exon 19 deletions or L858R, reported similar median OS for the two therapies (27.9 vs. 24.5 months, HR=0.86) but significantly longer time-to-treatment-failure (13.7 vs. 11.5 months, HR=0.75) and higher ORR (73% vs. 56%, p=0.0018) with afatinib[199]. Patients with metastatic NSCLC and common EGFR mutations who progressed on prior chemotherapy experienced an ORR of 50.0% (30/60) from afatinib in a Phase 4 trial[200]. As first-line therapy for NSCLC with EGFR exon 19 deletions or L858R, prospective or randomized Phase 2 trials have reported a median PFS of 10.2 months and OS of 24.8 months for patients unfit for chemotherapy[201] and an ORR of 72.5% (n=40, 1 CR), DCR of 100% (40/40), and median PFS and OS of 15.2 and 30.0 months, respectively, for elderly patients ≥70 years old[202]. A retrospective study of afatinib administered to Asian patients with NSCLC, 99% of whom were previously treated with erlotinib and/or gefitinib, reported an ORR of 27.4% (63/230) for patients with common sensitizing EGFR mutations and an ORR of 24.4% (105/431) for the entire cohort[203]. In a case report, a patient with NSCLC with exon 19 deletion and leptomeningeal metastases experienced an ongoing 16-month PR from afatinib in extracranial, brain, and leptomeningeal lesions[204]. For patients with erlotinib- or gefitinib-resistant NSCLC and EGFR mutations, Phase 2/3 studies of afatinib treatment have generally reported ORRs of only 7 to 9%[205-210] ; however, DCRs of more than 50% have been observed[209]. In a Phase 1b or observational study, patients with EGFR-mutated NSCLC who progressed on afatinib experienced further clinical benefit from subsequent treatment with afatinib and cetuximab[211] or osimertinib[212], respectively. Extensive clinical data have demonstrated that afatinib is effective for patients with EGFR-mutated advanced NSCLC, including exon 19 deletions and L858 mutations, as well as uncommon sensitizing mutations in exons 18 or 20[67,108,195,199,201,203,213] . Afatinib has also shown activity for patients with advanced NSCLC and ERBB2 mutations, most of which were exon 20 insertions[209,214-224] . The randomized Phase 3 LUX-Lung 8 trial comparing afatinib with erlotinib as second-line therapy for advanced lung squamous cell carcinoma (SCC) reported significantly longer median OS (7.9 vs. 6.8 months, HR=0.81), significantly longer median PFS (2.6 vs. 1.9 months, HR=0.81), and higher DCR (51% vs. 40%, p=0.002) for patients treated with afatinib[213]. For patients who progressed on afatinib monotherapy, additional clinical benefit has been reported from afatinib combined with paclitaxel[225].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Dacomitinib

Assay findings association

EGFR
exon 19 deletion (E746_A750del)

AREAS OF THERAPEUTIC USE

Dacomitinib is a second generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[67-68,195-196] , whereas data for patients with other tumor types are limited[70-75,197] . Patients with untreated advanced NSCLC and EGFR exon 19 deletions achieved an ORR of 76%[110] and a median OS of 34.1 months with dacomitinib[68].

SUPPORTING DATA

A randomized Phase 3 trial in patients with NSCLC with activating EGFR mutations (primarily L858R or exon 19 deletions) reported improved clinical benefit with first-line dacomitinib compared with gefitinib (median OS, 34.1 vs. 26.8 months, HR=0.760; median PFS, 14.7 vs. 9.2 months, HR=0.59)[110,226] ; median OS was 34.1 to 36.7 months and ORR was 74.9% to 79.3%, depending on the dosing regimen[227]. A pooled subgroup analysis of patients with NSCLC with activating EGFR mutations reported improved clinical efficacy with dacomitinib treatment compared with erlotinib (median PFS, 14.6 vs, 9.6 months, HR=0.717; median OS, 26.6 vs, 23.2 months, HR=0.737)[228]. Reduced efficacy of dacomitinib treatment in patients with NSCLC harboring the EGFR T790M mutation has been reported in multiple studies[229-231] . A Phase 1 trial of combination dacomitinib and a MEK1/2 inhibitor for patients with KRAS-mutated CRC, NSCLC, or pancreatic cancer reported 20/36 SDs and 16 PDs, however toxicity from this combination prevented long-term treatment in this patient population[232]. A Phase 2 study of dacomitinib in patients with NSCLC who had been previously treated with chemotherapy or erlotinib and were not selected for EGFR mutations reported an ORR of 4.5% (3/66)[230]. In one study, the combination of dacomitinib and crizotinib was ineffective and associated with high toxicity in patients with NSCLC[233].

Erlotinib

Assay findings association

EGFR
exon 19 deletion (E746_A750del)

AREAS OF THERAPEUTIC USE

Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression[65,234-236] .

SUPPORTING DATA

In one study, median PFS (4.1 vs. 11.7 months, HR=9.7) and median OS (14.1 vs. 47.0 months, HR=10.2) were significantly shorter for patients with non-small cell lung cancer (NSCLC) harboring EGFR L747_A750>P (n=6) relative to those with deletions affecting EGFR E746_A750 (n=24) treated with first-line erlotinib[237]. For patients with EGFR-mutated non-small cell lung cancer (NSCLC), the Phase 3 EURTAC trial improved PFS with first-line erlotinib relative to platinum-based chemotherapy (9.7 vs. 5.2 months, HR=0.37), though OS was not prolonged (22.9 vs 19.6 months, HR=0.92)[65,238] . This study and meta-analyses attribute the lack of OS benefit to the effectiveness of post-progression salvage therapy in the control arm[239]. A Phase 3 study reported similar efficacy of erlotinib and gefitinib for patients with EGFR-mutated NSCLC[240]. Patients with EGFR-mutated NSCLC have experienced PFS benefit with the addition of bevacizumab to erlotinib in the first-line setting in Phase 3 trials including the ARTEMIS-CTONG1509 trial for Chinese patients (17.9 vs. 11.2 months, HR=0.55)[241], the NEJ026 trial for Japanese patients (16.9 vs. 13.3 months, HR=0.605)[242-243] , and the international BEVERLY trial (15.4 vs. 9.7 months, HR=0.60)[244]; OS benefit has not been observed across these studies. In the maintenance setting, Phase 3 trials have reported significantly improved PFS with maintenance erlotinib following first-line platinum-based chemotherapy, with the largest benefit for patients with EGFR mutations[234,245] . In the neoadjuvant setting, a Phase 2 trial reported a numerically improved ORR and significantly longer PFS with erlotinib compared with chemotherapy for patients with EGFR-mutated advanced NSCLC[235]. In the placebo-controlled Phase 3 RELAY trial, the addition of ramucirumab to erlotinib improved PFS for previously untreated patients with NSCLC harboring EGFR L858R or exon 19 deletion (19.4 vs. 12.4 months, HR=0.59)[246].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Gefitinib

Assay findings association

EGFR
exon 19 deletion (E746_A750del)

AREAS OF THERAPEUTIC USE

Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy[236,247-252] , and responses have been reported for patients with EGFR-rearranged NSCLC[253-254] .

SUPPORTING DATA

Gefitinib achieved an ORR of 69.8% and OS of 19.2 months as first-line treatment for Caucasian patients with non-small cell lung cancer (NSCLC) and EGFR sensitizing mutations[66]. Phase 3 studies for Japanese patients[249,255] and East Asian patients[250,256] with EGFR-mutated NSCLC reported longer PFS but not longer OS on first-line gefitinib compared with cisplatin and docetaxel or carboplatin and paclitaxel. Retrospective analysis of East Asian patients receiving first-line gefitinib reported greatest PFS benefit among patients with EGFR exon 19 insertions or deletions and shortest PFS for those with exon 20 insertions (1.2 months)[257]. Two Phase 3 trials of the combination gefitinib plus pemetrexed and carboplatin compared with gefitinib alone for patients with advanced NSCLC harboring EGFR activating mutations reported significantly higher ORRs (75.3% and 84% vs. 62.5% and 67%), longer median PFS (16 and 20.9 months vs. 8 and 11.9 months), and longer median OS (50.9 months and not reached vs. 17 and 38.8 months) with combination treatment; however, combination treatment was associated with increased Grade 3 or higher adverse events[258-259] . In a Phase 1 study for treatment-naive patients with NSCLC, 63% (19/30) of patients experienced PR from the combination of gefitinib and the PD-L1 inhibitor durvalumab[260].

Osimertinib

Assay findings association

EGFR
exon 19 deletion (E746_A750del)

AREAS OF THERAPEUTIC USE

Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer[69,109,253,261-262] . Patients with untreated advanced NSCLC and EGFR exon 19 deletions or L858R mutations achieved an ORR of 80% and a median PFS of 21.4 and 14.4 months, respectively[109].

SUPPORTING DATA

The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced NSCLC and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858)[109,263] . In the Phase 3 ADAURA study, patients with early Stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer PFSs on osimertinib compared to placebo in the adjuvant setting (not reached vs. 28.1 months; HR=0.21)[264]. A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months[69]. A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/19), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213)[265]. The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47)[266]. The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively[267].

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
APC

ALTERATION
Y158fs*12

RATIONALE
Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta-catenin interaction inhibitors.

NCT03833700

PHASE 1

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

TARGETS
CBP, Beta-catenin

LOCATIONS: Fukuoka (Japan), Nagaizumi-cho (Japan), Chuo Ku (Japan), Kashiwa (Japan)

NCT04008797

PHASE 1

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

TARGETS
CBP, Beta-catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT

LOCATIONS: Osakasayama (Japan), Chuo-Ku (Japan), Kashiwa (Japan)

NCT03264664

PHASE 1

Study of E7386 in Participants With Selected Advanced Neoplasms

TARGETS
CBP, Beta-catenin

LOCATIONS: Sutton (United Kingdom), Manchester (United Kingdom), Glasgow (United Kingdom)

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
EGFR

ALTERATION
exon 19 deletion (E746_A750del)

RATIONALE
EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT04487080

PHASE 3

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

TARGETS
MET, EGFR

LOCATIONS: Malvern (Australia), Heidelberg (Australia), Wollongong (Australia), Bedford Park (Australia), Westmead (Australia), Woolloongabba (Australia), Nedlands (Australia), Johor Bahru (Malaysia), Kuantan (Malaysia), Petaling Jaya (Malaysia)

NCT03497767

PHASE 2

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

TARGETS
EGFR

LOCATIONS: Melbourne (Australia), Sydney (Australia), Newcastle (Australia), Brisbane (Australia), Singapore (Singapore)

NCT03783403

PHASE 1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

TARGETS
CD20, EGFR, SIRP-alpha

LOCATIONS: Melbourne (Australia), Heidelberg (Australia), Seoul (Korea, Republic of), Villejuif CEDEX (France), California, Oregon, Arizona, Edmonton (Canada), Texas

NCT04721015

PHASE 1

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

TARGETS
EGFR

LOCATIONS: Heidelberg (Australia), Wollongong (Australia), Tainan (Taiwan), Taoyuan City (Taiwan), Fukuoka-shi (Japan), Chuo-ku (Japan), Kashiwa-shi (Japan), Seoul (Korea, Republic of), Goyang (Korea, Republic of), Haifa (Israel)

NCT02609776

PHASE 1

A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

TARGETS
MET, EGFR

LOCATIONS: Heidelberg (Australia), Kogarah (Australia), Camperdown (Australia), Woolloongabba (Australia), Murdoch (Australia), Kaohsiung (Taiwan), Taichung (Taiwan), Taipei City (Taiwan), Taipei (Taiwan), Guangzhou (China)

NCT03755102

PHASE NULL

A Study of Dacomitinib in Patients With Metastatic EGFR Mutant Lung Cancer Previously Treated With Osimertinib

TARGETS
ERBB4, EGFR, ERBB2

LOCATIONS: New Jersey, New York

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

CLINICAL TRIALS

NCT04778800

PHASE NULL

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

TARGETS
EGFR

LOCATIONS: Zhengzhou (China)

NCT04816838

PHASE NULL

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

TARGETS
EGFR

LOCATIONS: Seoul (Korea, Republic of)

NCT04143607

PHASE 3

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

TARGETS
EGFR

LOCATIONS: Nanjing (China), Beijing (China)

NCT04181060

PHASE 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

TARGETS
EGFR, VEGFA

LOCATIONS: Hawaii, California

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
FANCL

ALTERATION
R68*

RATIONALE
On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04123366

PHASE 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

TARGETS
PARP, PD-1

LOCATIONS: Clayton (Australia), Blacktown (Australia), Southport (Australia), Nedlands (Australia), Fukuoka (Japan), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Seongnam-si (Korea, Republic of)

NCT04644068

PHASE 1/2

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

TARGETS
ERBB2, TROP2, PARP

LOCATIONS: Melbourne (Australia), Koto-ku (Japan), Chuo-ku (Japan), Seoul (Korea, Republic of), Texas, Oklahoma, Warszawa (Poland), Budapest (Hungary), Gdynia (Poland), Brno (Czechia)

NCT03742895

PHASE 2

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

TARGETS
PARP

LOCATIONS: Darlinghurst (Australia), Port Macquarie (Australia), Nedlands (Australia), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Berazategui (Argentina), Ciudad de Buenos Aires (Argentina), Buenos Aires (Argentina), California

NCT04380636

PHASE 3

Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

TARGETS
PD-L1, PARP, PD-1

LOCATIONS: Bangkok (Thailand), Shenzhen (China), Khon Kaen (Thailand), Xiamen (China), Fuzhou (China), Chiang Mai (Thailand), Nanchang (China), Hangzhou (China), Kurume (Japan), Shanghai (China)

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), California, New York, Villejuif (France), Cambridge (United Kingdom), Massachusetts, Sutton (United Kingdom)

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), London (Canada), Toronto (Canada), Kingston (Canada), Ottawa (Canada), Montreal (Canada)

NCT04497116

PHASE 1/2

Study of RP-3500 in Advanced Solid Tumors

TARGETS
ATR, PARP

LOCATIONS: Texas, Tennessee, Illinois, Copenhagen (Denmark), North Carolina, Toronto (Canada), New York, Newcastle Upon Tyne (United Kingdom), Rhode Island, Massachusetts

NCT04991480

PHASE 1/2

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

TARGETS
PARP, Pol theta

LOCATIONS: Texas, Oklahoma, Tennessee, Florida, New York, London (United Kingdom)

NCT04550494

PHASE 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

TARGETS
PARP

LOCATIONS: Oklahoma, Maryland

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TSC1

ALTERATION
G464fs*68

RATIONALE
Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT02693535

PHASE 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, CSF1R, KIT, RET, mTOR, EGFR, ERBB2, MEK, BRAF, SMO, DDR2, PARP, PD-1, CTLA-4, ERBB4

LOCATIONS: Hawaii, California

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO

LOCATIONS: Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), London (Canada), Toronto (Canada), Kingston (Canada), Ottawa (Canada), Montreal (Canada)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT03203525

PHASE 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

TARGETS
VEGFA, mTOR

LOCATIONS: Texas

NCT04185831

PHASE 2

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

TARGETS
PD-L1, MEK, mTOR

LOCATIONS: Uppsala (Sweden), Gothenburg (Sweden)

NCT01737502

PHASE 1/2

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

TARGETS
mTOR

LOCATIONS: Florida

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT01582191

PHASE 1

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

TARGETS
mTOR, EGFR, SRC, RET, VEGFRs

LOCATIONS: Texas

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC A731T	***AURKB*** R139S	***FGFR2*** V532L	***KMT2A (MLL)*** P2502H
MDM2 Q414H	***SPEN*** R3193Q	***TSC2*** K258E	

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*	*TET2*	*TGFBR2*	*TIPARP*
TNFAIP3	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*
WT1	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*				

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV1*
ETV4	*ETV5*	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*
KMT2A (MLL)	*MSH2*	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*
RAF1	*RARA*	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***
TMPRSS2								

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes. Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version 6.3.0

The median exon coverage for this sample is 567x

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Warth A, et al. Virchows Arch. (2016) pmid: 26637197
7. Ninomiya H, et al. Br. J. Cancer (2006) pmid: 16641899
8. Vanderwalde A, et al. Cancer Med (2018) pmid: 29436178
9. Zang YS, et al. Cancer Med (2019) pmid: 31270941
10. Dudley JC, et al. Clin. Cancer Res. (2016) pmid: 26880610
11. Takamochi K, et al. Lung Cancer (2017) pmid: 28676214
12. Pylkkänen L, et al. Environ. Mol. Mutagen. (1997) pmid: 9329646
13. Gonzalez R, et al. Ann. Oncol. (2000) pmid: 11061602
14. Chen XQ, et al. Nat. Med. (1996) pmid: 8782463
15. Merlo A, et al. Cancer Res. (1994) pmid: 8174113
16. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
17. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
18. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
19. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
20. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
21. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
22. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
23. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
24. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
25. Cristescu R, et al. Science (2018) pmid: 30309915
26. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
27. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
28. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
29. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
30. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
31. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
32. Rizvi NA, et al. Science (2015) pmid: 25765070
33. Colli LM, et al. Cancer Res. (2016) pmid: 27197178
34. Wang VE, et al. J Immunother Cancer (2017) pmid: 28923100
35. Carbone DP, et al. N. Engl. J. Med. (2017) pmid: 28636851
36. Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640
37. Forde PM, et al. N. Engl. J. Med. (2018) pmid: 29658848
38. Miao D, et al. Nat. Genet. (2018) pmid: 30150660
39. Chae YK, et al. Clin Lung Cancer (2019) pmid: 30425022
40. Paz-Ares et al., 2019; ESMO Abstract LBA80
41. Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796
42. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
43. Spigel et al., 2016; ASCO Abstract 9017
44. Xiao D, et al. Oncotarget (2016) pmid: 27009843
45. Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269
46. Govindan R, et al. Cell (2012) pmid: 22980976
47. Ding L, et al. Nature (2008) pmid: 18948947
48. Imielinski M, et al. Cell (2012) pmid: 22980975
49. Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028
50. Stein et al., 2019; DOI: 10.1200/PO.18.00376
51. Meng G, et al. PLoS One (2022) pmid: 35113949
52. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
53. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
54. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
55. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
56. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
57. Johnson BE, et al. Science (2014) pmid: 24336570
58. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
59. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
60. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
61. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
62. Nature (2012) pmid: 22810696
63. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
64. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
65. Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168
66. Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064
67. Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960
68. Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379
69. Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549
70. Hong MH, et al. Cancer (2020) pmid: 32749686
71. Kim HS, et al. Oncotarget (2015) pmid: 26462025
72. Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851
73. Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840
74. Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047
75. Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886
76. Leighl et al., 2021; ESMO Abstract 1192MO
77. Cho et al., 2020; ESMO Abstract 1258O
78. Bauml et al., 2021; ASCO Abstract 9006
79. Shu et al., 2021; ESMO Abstract 1193MO
80. Jänne PA, et al. Cancer Discov (2021) pmid: 34548309
81. Ahn MJ, et al. Lancet Respir Med (2017) pmid: 29056570
82. Yang Z, et al. Sci Transl Med (2016) pmid: 27928026
83. Ahn MJ, et al. Lancet Oncol (2019) pmid: 31587882
84. Lin L, et al. Lung Cancer (2022) pmid: 35248866
85. Reck M, et al. Lancet Respir Med (2019) pmid: 30922878
86. Socinski MA, et al. J Thorac Oncol (2021) pmid: 34311108
87. Socinski MA, et al. N. Engl. J. Med. (2018) pmid: 29863955
88. Lu et al., 2021; ESMO Abstract VP9-2021
89. Vallee A, et al. Int. J. Oncol. (2013) pmid: 23934203
90. Nature (2014) pmid: 25079552
91. Nature (2012) pmid: 22960745
92. Watzka SB, et al. Eur J Cardiothorac Surg (2010) pmid: 20353893
93. Liang Z, et al. BMC Cancer (2010) pmid: 20637128
94. Grob TJ, et al. Lung Cancer (2013) pmid: 23238037
95. Park S, et al. Histol. Histopathol. (2012) pmid: 22207554
96. Dobashi Y, et al. Hum. Pathol. (2011) pmid: 21040950
97. Ludovini V, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23314677
98. Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818
99. Kim SH, et al. Histol. Histopathol. (2012) pmid: 22419022
100. Lee JS, et al. Ann. Surg. Oncol. (2013) pmid: 23525704
101. Oakley GJ, et al. J Thorac Oncol (2011) pmid: 21587084
102. Marks JL, et al. J Thorac Oncol (2008) pmid: 18303429
103. Izar B, et al. Ann. Thorac. Surg. (2013) pmid: 23932319
104. Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605
105. Lynch TJ, et al. N. Engl. J. Med. (2004) pmid: 15118073
106. Paez JG, et al. Science (2004) pmid: 15118125
107. Pao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15329413
108. Yang JC, et al. Lancet Oncol. (2015) pmid: 25589191
109. Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359
110. Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502
111. Gilmer TM, et al. Cancer Res. (2008) pmid: 18199554
112. Foster SA, et al. Cancer Cell (2016) pmid: 26996308
113. Zhan T, et al. Oncogene (2017) pmid: 27617575
114. Jung YS, et al. Exp Mol Med (2020) pmid: 32037398
115. Krishnamurthy N, et al. Cancer Treat Rev (2018) pmid: 29169144
116. Kawazoe et al., 2021; ESMO Abstract 473P
117. Yamada K, et al. Cancer Res (2021) pmid: 33408116
118. Kanda Y, et al. Biochem Biophys Res Commun (2022) pmid: 34837838
119. Ohgaki H, et al. Cancer Lett. (2004) pmid: 15072829
120. Sanz-Ortega J, et al. Pathol. Res. Pract. (1999) pmid: 10549031
121. Poursoltan P, et al. Lung Cancer (2012) pmid: 22542170
122. Zhang Y, et al. Cancer Lett. (2011) pmid: 21255913
123. Virmani AK, et al. Clin. Cancer Res. (2001) pmid: 11448917
124. Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044
125. J. Natl. Cancer Inst. (2014) pmid: 24309006
126. Lu Y, et al. PLoS Med. (2006) pmid: 17194181
127. Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339
128. Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860
129. Eklof Spink K, et al. EMBO J. (2001) pmid: 11707392
130. Liu J, et al. J. Mol. Biol. (2006) pmid: 16753179
131. Dikovskaya D, et al. J. Cell. Sci. (2010) pmid: 20144988
132. Murphy SJ, et al. Dig. Dis. Sci. (2007) pmid: 17410430
133. Aretz S, et al. Hum. Mutat. (2004) pmid: 15459959
134. Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591
135. Annu Rev Pathol (2011) pmid: 21090969
136. Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223
137. Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006
138. O'Malley et al., 2017; AACR-NCI-EORTC Abstract LB-A12
139. Dougherty et al., 2014; ASCO Abstract 5536
140. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
141. Qu X, et al. Blood (2019) pmid: 30446494
142. Pace P, et al. EMBO J. (2002) pmid: 12093742
143. Deakyne JS, et al. Biochemistry Mosc. (2011) pmid: 21568838
144. Alpi A, et al. Mol. Cell. Biol. (2007) pmid: 17938197
145. Alpi AF, et al. Mol. Cell (2008) pmid: 19111657
146. Meetei AR, et al. Nat. Genet. (2003) pmid: 12973351
147. Machida YJ, et al. Mol. Cell (2006) pmid: 16916645
148. Hodson C, et al. J. Biol. Chem. (2011) pmid: 21775430
149. Hodson C, et al. Structure (2014) pmid: 24389026
150. Seki S, et al. Genes Cells (2007) pmid: 17352736
151. Ali AM, et al. Hum. Mutat. (2009) pmid: 19405097
152. Fostira F, et al. Breast Cancer Res. Treat. (2018) pmid: 29335925
153. Hart SN, et al. BMJ Open (2016) pmid: 27084275
154. Del Valle J, et al. Cancers (Basel) (2020) pmid: 32235514
155. Chandrasekharappa SC, et al. Blood (2013) pmid:

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

23613520
156. Dicks E, et al. Oncotarget (2017) pmid: 28881617
157. Tee AR, et al. Curr. Biol. (2003) pmid: 12906785
158. Mallela K, et al. Mol Cell Biochem (2021) pmid: 33575875
159. Adib E, et al. Clin Cancer Res (2021) pmid: 33727259
160. Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662
161. Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302
162. Ali SM, et al. Eur. Urol. (2015) pmid: 25796537
163. Lim SM, et al. Oncotarget (2016) pmid: 26859683
164. Kwiatkowski DJ, et al. Clin. Cancer Res. (2016) pmid: 26831717
165. Hamieh L, et al. PLoS Genet (2018) pmid: 30256787
166. Roldan-Romero JM, et al. Int J Cancer (2020) pmid: 31335987
167. Wagner AJ, et al. J Clin Oncol (2021) pmid: 34637337
168. Kopparthy P, et al. Cureus (2021) pmid: 34123648
169. Dickson et al., 2021; ASCO Abstract 3111
170. Liang MC, et al. Oncogene (2010) pmid: 19966866
171. Fuchs A, et al. Diagn Pathol (2014) pmid: 24593867
172. Inoki K, et al. Genes Dev. (2003) pmid: 12869586
173. Miloloza A, et al. Hum. Mol. Genet. (2000) pmid: 10915759
174. Hoogeveen-Westerveld M, et al. Biochim. Biophys. Acta (2010) pmid: 20547222
175. Hodges AK, et al. Hum. Mol. Genet. (2001) pmid: 11741833
176. Ann. N. Y. Acad. Sci. (1991) pmid: 2039135
177. van Slegtenhorst M, et al. Science (1997) pmid: 9242607
178. Crino PB, et al. N. Engl. J. Med. (2006) pmid: 17005952
179. Curatolo P, et al. Lancet (2008) pmid: 18722871
180. Zehir A, et al. Nat. Med. (2017) pmid: 28481359
181. Bailey MH, et al. Cell (2018) pmid: 29625053
182. Bolton KL, et al. Nat Genet (2020) pmid: 33106634
183. Scheuermann JC, et al. Nature (2010) pmid: 20436459
184. Cho YS, et al. J. Biol. Chem. (2006) pmid: 16606617
185. Park UH, et al. J. Biol. Chem. (2011) pmid: 21047783
186. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
187. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
188. Xie M, et al. Nat. Med. (2014) pmid: 25326804
189. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
190. Severson EA, et al. Blood (2018) pmid: 29678827
191. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
192. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
193. Chabon JJ, et al. Nature (2020) pmid: 32269342
194. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
195. Wu YL, et al. Lancet Oncol. (2014) pmid: 24439929
196. Passaro et al., 2019; ELCC Abstract 1150
197. Audet et al., 2013; ASCO Abstract 6041
198. Lau SC, et al. Clin Lung Cancer (2019) pmid: 31178389
199. Paz-Ares L, et al. Ann. Oncol. (2017) pmid: 28426106
200. Thongprasert S, et al. Lung Cancer Manag (2019) pmid: 31807143
201. Januszewski et al., 2018; IASLC WCLC Abstract P1.13-17
202. Suzuki et al., 2018; IASLC WCLC Abstract P1.01-92
203. Chang et al., 2018; IASLC WCLC Abstract P1.01-11
204. Llinás-Quintero N, et al. Case Rep Oncol Med (2019) pmid: 31637072
205. Miller VA, et al. Lancet Oncol. (2012) pmid: 22452896
206. Chen X, et al. Lung Cancer (2013) pmid: 23664448
207. Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963
208. Landi L, et al. Clin Lung Cancer (2014) pmid: 25242668
209. De Grève J, et al. Lung Cancer (2015) pmid: 25682316
210. Yang JC, et al. Lancet Oncol. (2015) pmid: 26051236
211. Horn L, et al. Lung Cancer (2017) pmid: 29110849
212. Yamamoto N, et al. Adv Ther (2020) pmid: 31863283
213. Soria JC, et al. Lancet Oncol. (2015) pmid: 26156651
214. Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613
215. Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684
216. Greulich H, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22908275
217. Gow CH, et al. J Thorac Oncol (2015) pmid: 26134234
218. Mazières J, et al. Ann. Oncol. (2016) pmid: 26598547
219. Mazières J, et al. J. Clin. Oncol. (2013) pmid: 23610105
220. De Grève J, et al. Lung Cancer (2012) pmid: 22325357
221. Li BT, et al. Lung Cancer (2015) pmid: 26559459
222. Costa DB, et al. J Thorac Oncol (2016) pmid: 26964772
223. Yuan B, et al. Front Oncol (2020) pmid: 32477948
224. Fang W, et al. Oncologist (2019) pmid: 31748336
225. Schuler M, et al. Ann. Oncol. (2016) pmid: 26646759
226. Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437
227. Wu et al., 2018; WCLC abstract MA26.11
228. Ramalingam SS, et al. Ann. Oncol. (2016) pmid: 26768165
229. Yu HA, et al. Lung Cancer (2017) pmid: 29191595
230. Reckamp KL, et al. Cancer (2014) pmid: 24501009
231. Jänne PA, et al. Clin. Cancer Res. (2011) pmid: 21220471
232. van Geel RMJM, et al. Br. J. Cancer (2020) pmid: 32147669
233. Jänne PA, et al. J Thorac Oncol (2016) pmid: 26899759
234. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
235. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
236. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
237. Truini A, et al. Clin. Cancer Res. (2019) pmid: 31182434
238. Leon et al., 2014; doi.org/10.1093/annonc/mdu349.52
239. Lee CK, et al. J. Natl. Cancer Inst. (2017) pmid: 28376144
240. Yang JJ, et al. Br. J. Cancer (2017) pmid: 28103612
241. Zhou Q, et al. Cancer Cell (2021) pmid: 34388377
242. Kawashima Y, et al. Lancet Respir Med (2022) pmid: 34454653
243. Saito H, et al. Lancet Oncol (2019) pmid: 30975627
244. Piccirillo et al., 2021; ESMO Abstract 12070
245. Faehling M, et al. J Cancer Res Clin Oncol (2018) pmid: 29687154
246. Nakagawa K, et al. Lancet Oncol. (2019) pmid: 31591063
247. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
248. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
249. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
250. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680
251. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
252. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
253. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
254. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
255. Yoshioka H, et al. Ann. Oncol. (2019) pmid: 31553438
256. Fukuoka M, et al. J. Clin. Oncol. (2011) pmid: 21670455
257. Sutiman N, et al. J Thorac Oncol (2017) pmid: 27908825
258. Noronha V, et al. J. Clin. Oncol. (2019) pmid: 31411950
259. Hosomi Y, et al. J. Clin. Oncol. (2020) pmid: 31682542
260. Creelan BC, et al. Br J Cancer (2021) pmid: 33012782
261. Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755
262. Kim et al., 2021; DOI: 10.1200/PO.20.00296
263. Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012
264. Herbst et al., 2020; ASCO Abstract LBA5
265. Kenmotsu et al., 2021; ESMO Abstract LBA44
266. Soo et al., 2021; ESMO Abstract VP3-2021
267. Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298

Electronically signed by Erik Williams, M.D. |
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531 Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309 Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Roche Products (NZ) Ltd. 98 Carlton Gore Road, Newmarket, Auckland 1023. PO Box 109113, Newmarket, Auckland 1149.
Tel: 0800 880 177 | APAC.foundation@roche.com | www.foundationmedicine.co.nz M-NZ-00000257v2/SEP2022